Skip to main content
SpringerLink
Log in

Better quality of life in patients offered financial incentives for taking anti-psychotic medication: Linked to improved adherence or more money?

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

In a randomised controlled trial, patients were offered financial incentives to improve their adherence to anti-psychotic maintenance medication. Compared to a control group without the incentives, they had an improved adherence and also better subjective quality of life (SQOL) after 1 year. This paper explores the question as to whether this improvement in SQOL was associated with the amount of money received or with the improved adherence itself.

Method

A secondary analysis was performed using data of the experimental group in the trial. Adherence was assessed as the percentage of all prescribed long-acting anti-psychotic injections that were taken by the patient. In regression models, we tested whether changes in medication adherence and/or the amount of incentives received over the 12-month period was associated with SQOL, as rated on the DIALOG scale.

Results

Adherence changed from 68.49 % at baseline to 88.23 % (mean difference in adherence = 19.59 %, SD = 17.52 %). The total amount of incentives received within the 1-year study period varied between £75 and £735, depending on the treatment cycle and the number of long-acting injections taken. Improvement in adherence was found to be a significant predictor of better subjective quality of life (β = 0.014, 95 % CI 0.003–0.025, p = 0.014), whilst the amount of incentives received was not (β = 0.0002, 95 % CI −0.002 to 0.002, p = 0.818).

Conclusion

Improved medication adherence is associated with a more favourable SQOL. This underlines the clinical relevance of improved adherence in response to financial incentives in this patient group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adelufosi, A. O., et al. (2012). Medication adherence and quality of life among Nigerian outpatients with schizophrenia. General Hospital Psychiatry, 34(1), 72–79.

    Article  PubMed  Google Scholar 

  2. Hayhurst, K. P., et al. (2014). Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. European Psychiatry, 29(3), 191–196.

    Article  CAS  PubMed  Google Scholar 

  3. Javadpour, A., et al. (2013). The impact of a simple individual psycho-education program on quality of life, rate of relapse and medication adherence in bipolar disorder patients. Asian Journal of Psychiatry, 6(3), 208–213.

    Article  PubMed  Google Scholar 

  4. Montes, J. M., et al. (2012). A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. Psychiatry Research, 200(2–3), 89–95.

    Article  PubMed  Google Scholar 

  5. Staring, A. B., et al. (2010). Treatment adherence therapy in people with psychotic disorders: Randomised controlled trial. British Journal of Psychiatry, 197(6), 448–455.

    Article  CAS  PubMed  Google Scholar 

  6. Valenstein, M., et al. (2011). Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophrenia Bulletin, 37(4), 727–736.

    Article  PubMed  Google Scholar 

  7. Gray, R., et al. (2006). Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. British Journal of Psychiatry, 189, 508–514.

    Article  PubMed  Google Scholar 

  8. O’Donnell, C., et al. (2003). Compliance therapy: A randomised controlled trial in schizophrenia. BMJ, 327(7419), 834.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Priebe, S., et al. (2013). Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: Cluster randomised controlled trial. BMJ, 347, f5847.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Claassen, D., Fakhoury, W. K., Ford, R., & Priebe, S. (2007). Money for medication: Financial incentives to improve medication adherence in assertive outreach. Psychological Bulletin, 31, 4–7.

    Article  Google Scholar 

  11. Post, E. P., Cruz, M., & Harman, J. (2006). Incentive payments for attendance at appointments for depression among low-income African Americans. Psychiatric Services, 57(3), 414–416.

    Article  PubMed  Google Scholar 

  12. Roll, J. M., et al. (1998). Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: A feasibility study. Experimental and Clinical Psychopharmacology, 6(2), 157–161.

    Article  CAS  PubMed  Google Scholar 

  13. Tidey, J. W., O’Neill, S. C., & Higgins, S. T. (2002). Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Experimental and Clinical Psychopharmacology, 10(3), 241–247.

    Article  PubMed  Google Scholar 

  14. Helmus, T. C., et al. (2003). Reinforcement of counseling attendance and alcohol abstinence in a community-based dual-diagnosis treatment program: A feasibility study. Psychology of Addictive Behaviors, 17(3), 249–251.

    Article  PubMed  Google Scholar 

  15. Roll, J. M., Chermack, S. T., & Chudzynski, J. E. (2004). Investigating the use of contingency management in the treatment of cocaine abuse among individuals with schizophrenia: A feasibility study. Psychiatry Research, 125(1), 61–64.

    Article  PubMed  Google Scholar 

  16. Shaner, A., et al. (1997). Monetary reinforcement of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatric Services, 48(6), 807–810.

    Article  CAS  PubMed  Google Scholar 

  17. Sigmon, S. C., et al. (2000). Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: A feasibility study. Experimental and Clinical Psychopharmacology, 8(4), 509–517.

    Article  CAS  PubMed  Google Scholar 

  18. World Health Organization. (1993). The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research. Geneva: World Health Organization.

    Google Scholar 

  19. Priebe, S., et al. (2007). Structured patient-clinician communication and 1-year outcome in community mental healthcare: Cluster randomised controlled trial. British Journal of Psychiatry, 191, 420–426.

    Article  PubMed  Google Scholar 

  20. Priebe, S., et al. (1999). Application and results of the Manchester Short Assessment of Quality of Life (MANSA). International Journal of Social Psychiatry, 45(1), 7–12.

    Article  CAS  PubMed  Google Scholar 

  21. Bjorkman, T., & Svensson, B. (2005). Quality of life in people with severe mental illness. Reliability and validity of the Manchester Short Assessment of Quality of Life (MANSA). Nordic Journal of Psychiatry, 59(4), 302–306.

    Article  PubMed  Google Scholar 

  22. Priebe, S., et al. (2012). Patient-reported outcome data generated in a clinical intervention in community mental health care—Psychometric properties. BMC Psychiatry, 12, 113.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Chuang, J. H., Hripcsak, G., & Heitjan, D. F. (2002). Design and analysis of controlled trials in naturally clustered environments: Implications for medical informatics. Journal of the American Medical Informatics Association, 9(3), 230–238.

    Article  PubMed  PubMed Central  Google Scholar 

  24. StataCorp LP. (2007). Stata statistical software: Release 10. College Station, TX: StataCorp LP.

    Google Scholar 

  25. Paul-Ebhohimhen, V., & Avenell, A. (2008). Long-term Effects of financial incentives in treatments for obesity: A systematic review of randomised controlled trials. Obesity Research, 9(9), 355–367.

    Article  CAS  Google Scholar 

  26. Staring, A. B., et al. (2009). Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life. Schizophrenia Research, 113(1), 27–33.

    Article  CAS  PubMed  Google Scholar 

  27. Puschner, B., et al. (2009). Course of adherence to medication and quality of life in people with schizophrenia. Psychiatry Research, 165(3), 224–233.

    Article  PubMed  Google Scholar 

  28. Priebe, S., et al. (2011). Association between symptoms and quality of life in patients with schizophrenia: A pooled analysis of changes over time. Schizophrenia Research, 133(1–3), 17–21.

    Article  PubMed  Google Scholar 

Download references

Funding

This trial was funded by the National Institute of Health Research Health Technology Assessment (Project No. 07/60/43). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS, or the Department of Health.

Author information

Authors and Affiliations

  1. Unit for Social and Community Psychiatry, WHO Collaborating Centre for Mental Health for Service Development, Queen Mary University of London, London, UK

    Katherine Moran & Stefan Priebe

Authors
  1. Katherine Moran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Priebe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Priebe.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (NRES reference number 09/H0710/35) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moran, K., Priebe, S. Better quality of life in patients offered financial incentives for taking anti-psychotic medication: Linked to improved adherence or more money?. Qual Life Res 25, 1897–1902 (2016). https://doi.org/10.1007/s11136-016-1238-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-016-1238-1

Keywords

Search

Navigation